Table 2.
Baseline fold change expression of microRNAs in whole synovial tissue comparing seronegative UPIA patients who achieved diagnosis of definite seronegative arthritis vs. UPIA patients who remained as UPIA during the follow-up.
| Diff UPIA vs. no-Diff UPIA | ||
|---|---|---|
| miRNA | Fold change | P-Value |
| hsa-let-7a-5p | 1.72 | 0.64274 |
| hsa-let-7b-5p | 15.06 | 0.58211 |
| hsa-let-7c-5p | 1.06 | 0.938401 |
| hsa-let-7d-5p | 1.16 | 0.589124 |
| hsa-let-7e-5p | 0.83 | 0.404177 |
| hsa-let-7f-5p | 1.31 | 0.75907 |
| hsa-let-7g-5p | 1.53 | 0.348485 |
| hsa-let-7i-5p | 1.01 | 0.637933 |
| hsa-miR-100-5p | 0.92 | 0.873711 |
| hsa-miR-101-3p | 2.23 | 0.449745 |
| hsa-miR-106b-5p | 1.31 | 0.460063 |
| hsa-miR-125b-5p | 9.19 | 0.54778 |
| hsa-miR-126-3p | 1.00 | 0.731593 |
| hsa-miR-128-3p | 1.12 | 0.625592 |
| hsa-miR-130b-3p | 0.76 | 0.61418 |
| hsa-miR-132-3p | 0.63 | 0.383393 |
| hsa-miR-139-5p | 0.63 | 0.355359 |
| hsa-miR-142-3p | 2.63 | 0.438817 |
| hsa-miR-142-5p | 1.15 | 0.441401 |
| hsa-miR-145-5p | 0.80 | 0.78913 |
| hsa-miR-146a-5p | 0.99 | 0.699398 |
| hsa-miR-146b-5p | 1.57 | 0.274573 |
| hsa-miR-147a | 0.90 | 0.337146 |
| hsa-miR-148a-3p | 0.97 | 0.213462 |
| hsa-miR-150-5p | 1.50 | 0.228892 |
| hsa-miR-155-5p | 0.83 | 0.544259 |
| hsa-miR-15a-5p | 1.06 | 0.504269 |
| hsa-miR-15a-3p | 0.69 | 0.526566 |
| hsa-miR-15b-5p | 2.05 | 0.301488 |
| hsa-miR-16-5p | 1.83 | 0.450233 |
| hsa-miR-17-5p | 1.12 | 0.471384 |
| hsa-miR-17-3p | 1.00 | 0.554158 |
| hsa-miR-181a-5p | 0.66 | 0.616177 |
| hsa-miR-181b-5p | 0.69 | 0.189542 |
| hsa-miR-181c-5p | 0.65 | 0.629276 |
| hsa-miR-181d-5p | 0.54 | 0.05944 |
| hsa-miR-182-5p | 1.47 | 0.441483 |
| hsa-miR-184 | 0.41 | 0.141154 |
| hsa-miR-18a-5p | 1.65 | 0.454234 |
| hsa-miR-191-5p | 1.31 | 0.513057 |
| hsa-miR-195-5p | 1.87 | 0.449673 |
| hsa-miR-199a-5p | 0.60 | 0.751729 |
| hsa-miR-19a-3p | 1.64 | 0.447654 |
| hsa-miR-19b-3p | 1.67 | 0.449978 |
| hsa-miR-204-5p | 0.38 | 0.25995 |
| hsa-miR-20a-5p | 1.32 | 0.457404 |
| hsa-miR-20b-5p | 1.48 | 0.455427 |
| hsa-miR-21-5p | 0.66 | 0.569126 |
| hsa-miR-210-3p | 0.81 | 0.971131 |
| hsa-miR-214-3p | 0.44 | 0.023626 |
| hsa-miR-221-3p | 0.88 | 0.813492 |
| hsa-miR-222-3p | 0.74 | 0.292096 |
| hsa-miR-223-3p | 1.33 | 0.501084 |
| hsa-miR-23a-3p | 0.99 | 0.897427 |
| hsa-miR-23b-3p | 0.77 | 0.310103 |
| hsa-miR-24-3p | 1.23 | 0.699806 |
| hsa-miR-25-3p | 0.98 | 0.80932 |
| hsa-miR-26a-5p | 1.25 | 0.498431 |
| hsa-miR-26b-5p | 1.21 | 0.442715 |
| hsa-miR-27a-3p | 1.13 | 0.628788 |
| hsa-miR-27b-3p | 0.97 | 0.871495 |
| hsa-miR-28-5p | 0.78 | 0.516299 |
| hsa-miR-29a-3p | 1.01 | 0.862774 |
| hsa-miR-29b-3p | 1.30 | 0.460232 |
| hsa-miR-29c-3p | 1.23 | 0.55443 |
| hsa-miR-30a-5p | 1.05 | 0.586439 |
| hsa-miR-30b-5p | 1.03 | 0.537262 |
| hsa-miR-30c-5p | 1.34 | 0.423138 |
| hsa-miR-30d-5p | 0.97 | 0.598599 |
| hsa-miR-30e-5p | 1.10 | 0.544092 |
| hsa-miR-31-5p | 0.89 | 0.307602 |
| hsa-miR-326 | 0.80 | 0.622988 |
| hsa-miR-331-3p | 0.54 | 0.40421 |
| hsa-miR-335-5p | 0.96 | 0.75784 |
| hsa-miR-342-3p | 1.12 | 0.545177 |
| hsa-miR-346 | 0.44 | 0.017843 |
| hsa-miR-34a-5p | 0.56 | 0.973224 |
| hsa-miR-365b-3p | 0.87 | 0.530566 |
| hsa-miR-423-5p | 0.72 | 0.62926 |
| hsa-miR-574-3p | 0.86 | 0.895815 |
| hsa-miR-92a-3p | 1.44 | 0.427582 |
| hsa-miR-93-5p | 1.21 | 0.484929 |
| hsa-miR-98-5p | 0.62 | 0.148112 |
| hsa-miR-99a-5p | 0.83 | 0.971675 |
miRNA profiling was analysed in the whole synovial tissue total RNA samples obtained from seronegative UPIA patients z(6 UPIA patients who reached a definite diagnosis of seronegative arthritis during the follow-up and 4 UPIA patients who remained as UPIA); Columns highlighted in bold represent miRNAs that show significant differential expression between the two groups (p < 0.05); Red-highlighted values indicate up-regulated miRNA species whereas green-highlighted values indicate down-regulated miRNA species in ST; MiRNA, microRNA.